Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Shareholders' Equity for the year ending December 31, 2023: USD 168.82 M

Allakos Inc Shareholders' Equity is USD 168.82 M for the year ending December 31, 2023, a -45.62% change year over year. Shareholders' Equity is the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Allakos Inc Shareholders' Equity for the year ending December 31, 2022 was USD 310.43 M, a -30.31% change year over year.
Allakos Inc Shareholders' Equity for the year ending December 31, 2021 was USD 445.48 M, a -31.93% change year over year.
Allakos Inc Shareholders' Equity for the year ending December 31, 2020 was USD 654.39 M, a 32.01% change year over year.
Allakos Inc Shareholders' Equity for the year ending December 31, 2019 was USD 495.72 M, a 169.42% change year over year.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends